In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.72B ...

The dip reflects shifting expectations around US monetary policy, with investors bracing for a tighter US Federal Reserve stance in 2025 under Donald Trump’s administration. Anticipation of higher ...

The logo was made by the Salvadoran artist Christian Chavarría Ayala, who placed Christ in the center of the cross. A news brief published by L'Osservatore Romano (LOR) in early October ...